Silymarin

A novel antioxidant with antiglycation and antiinflammatory properties in vitro and in vivo

Chi H. Wu, Shang Ming Huang, Gow Chin Yen

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

The current study was designed to evaluate the effects of silymarin (SM) on advanced glycation endproduct (AGE) formation and monocyte activation induced by S100b, a specific ligand of receptor for AGEs. The in vivo verification of antiglycation, antioxidant, and antiinflammatory capacities was examined by 12 weeks of SM administration in streptozotocin-diabetic rats. In vitro glycation assays demonstrated that SM exerted marked inhibition during the late stages of glycation and subsequent crosslinking. Dual action mechanisms, namely, antioxidant and reactive carbonyl trapping activities, may contribute to its antiglycation effect. SM produced a significant decrease in monocytic interleukin-1β and COX-2 levels and prevented oxidant formation caused by S100b, which appeared to be mediated by inhibition of p47phox membrane translocation. Chromatin immunoprecipitation demonstrated that S100b increased the recruitment of nuclear factor-kappaB transcription factor as well as cAMP response element-binding-binding protein and coactivator-associated arginine methyltransferase-1 cofactors to the interleukin-1β promoter, whereas these changes were inhibited with SM treatment. In vivo, SM reduced tissue AGE accumulation, tail collagen crosslinking, and concentrations of plasma glycated albumin. Levels of oxidative and inflammatory biomarkers were also significantly decreased in SM-treated groups compared with the diabetic group. These data suggest that SM supplementation may reduce the burden of AGEs in diabetics and may prevent resulting complications.

Original languageEnglish
Pages (from-to)353-366
Number of pages14
JournalAntioxidants and Redox Signaling
Volume14
Issue number3
DOIs
Publication statusPublished - Feb 1 2011
Externally publishedYes

Fingerprint

Silymarin
Anti-Inflammatory Agents
Antioxidants
Interleukin-1
Crosslinking
In Vitro Techniques
Chromatin Immunoprecipitation
Response Elements
Biomarkers
Streptozocin
Oxidants
Serum Albumin
Chromatin
Tail
Rats
Monocytes
Assays
Carrier Proteins
Transcription Factors
Collagen

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Clinical Biochemistry
  • Molecular Biology
  • Physiology

Cite this

Silymarin : A novel antioxidant with antiglycation and antiinflammatory properties in vitro and in vivo. / Wu, Chi H.; Huang, Shang Ming; Yen, Gow Chin.

In: Antioxidants and Redox Signaling, Vol. 14, No. 3, 01.02.2011, p. 353-366.

Research output: Contribution to journalArticle

Wu, Chi H. ; Huang, Shang Ming ; Yen, Gow Chin. / Silymarin : A novel antioxidant with antiglycation and antiinflammatory properties in vitro and in vivo. In: Antioxidants and Redox Signaling. 2011 ; Vol. 14, No. 3. pp. 353-366.
@article{f982f28bce7c4ef19ff8d6095b50af3f,
title = "Silymarin: A novel antioxidant with antiglycation and antiinflammatory properties in vitro and in vivo",
abstract = "The current study was designed to evaluate the effects of silymarin (SM) on advanced glycation endproduct (AGE) formation and monocyte activation induced by S100b, a specific ligand of receptor for AGEs. The in vivo verification of antiglycation, antioxidant, and antiinflammatory capacities was examined by 12 weeks of SM administration in streptozotocin-diabetic rats. In vitro glycation assays demonstrated that SM exerted marked inhibition during the late stages of glycation and subsequent crosslinking. Dual action mechanisms, namely, antioxidant and reactive carbonyl trapping activities, may contribute to its antiglycation effect. SM produced a significant decrease in monocytic interleukin-1β and COX-2 levels and prevented oxidant formation caused by S100b, which appeared to be mediated by inhibition of p47phox membrane translocation. Chromatin immunoprecipitation demonstrated that S100b increased the recruitment of nuclear factor-kappaB transcription factor as well as cAMP response element-binding-binding protein and coactivator-associated arginine methyltransferase-1 cofactors to the interleukin-1β promoter, whereas these changes were inhibited with SM treatment. In vivo, SM reduced tissue AGE accumulation, tail collagen crosslinking, and concentrations of plasma glycated albumin. Levels of oxidative and inflammatory biomarkers were also significantly decreased in SM-treated groups compared with the diabetic group. These data suggest that SM supplementation may reduce the burden of AGEs in diabetics and may prevent resulting complications.",
author = "Wu, {Chi H.} and Huang, {Shang Ming} and Yen, {Gow Chin}",
year = "2011",
month = "2",
day = "1",
doi = "10.1089/ars.2010.3134",
language = "English",
volume = "14",
pages = "353--366",
journal = "Antioxidants and Redox Signaling",
issn = "1523-0864",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Silymarin

T2 - A novel antioxidant with antiglycation and antiinflammatory properties in vitro and in vivo

AU - Wu, Chi H.

AU - Huang, Shang Ming

AU - Yen, Gow Chin

PY - 2011/2/1

Y1 - 2011/2/1

N2 - The current study was designed to evaluate the effects of silymarin (SM) on advanced glycation endproduct (AGE) formation and monocyte activation induced by S100b, a specific ligand of receptor for AGEs. The in vivo verification of antiglycation, antioxidant, and antiinflammatory capacities was examined by 12 weeks of SM administration in streptozotocin-diabetic rats. In vitro glycation assays demonstrated that SM exerted marked inhibition during the late stages of glycation and subsequent crosslinking. Dual action mechanisms, namely, antioxidant and reactive carbonyl trapping activities, may contribute to its antiglycation effect. SM produced a significant decrease in monocytic interleukin-1β and COX-2 levels and prevented oxidant formation caused by S100b, which appeared to be mediated by inhibition of p47phox membrane translocation. Chromatin immunoprecipitation demonstrated that S100b increased the recruitment of nuclear factor-kappaB transcription factor as well as cAMP response element-binding-binding protein and coactivator-associated arginine methyltransferase-1 cofactors to the interleukin-1β promoter, whereas these changes were inhibited with SM treatment. In vivo, SM reduced tissue AGE accumulation, tail collagen crosslinking, and concentrations of plasma glycated albumin. Levels of oxidative and inflammatory biomarkers were also significantly decreased in SM-treated groups compared with the diabetic group. These data suggest that SM supplementation may reduce the burden of AGEs in diabetics and may prevent resulting complications.

AB - The current study was designed to evaluate the effects of silymarin (SM) on advanced glycation endproduct (AGE) formation and monocyte activation induced by S100b, a specific ligand of receptor for AGEs. The in vivo verification of antiglycation, antioxidant, and antiinflammatory capacities was examined by 12 weeks of SM administration in streptozotocin-diabetic rats. In vitro glycation assays demonstrated that SM exerted marked inhibition during the late stages of glycation and subsequent crosslinking. Dual action mechanisms, namely, antioxidant and reactive carbonyl trapping activities, may contribute to its antiglycation effect. SM produced a significant decrease in monocytic interleukin-1β and COX-2 levels and prevented oxidant formation caused by S100b, which appeared to be mediated by inhibition of p47phox membrane translocation. Chromatin immunoprecipitation demonstrated that S100b increased the recruitment of nuclear factor-kappaB transcription factor as well as cAMP response element-binding-binding protein and coactivator-associated arginine methyltransferase-1 cofactors to the interleukin-1β promoter, whereas these changes were inhibited with SM treatment. In vivo, SM reduced tissue AGE accumulation, tail collagen crosslinking, and concentrations of plasma glycated albumin. Levels of oxidative and inflammatory biomarkers were also significantly decreased in SM-treated groups compared with the diabetic group. These data suggest that SM supplementation may reduce the burden of AGEs in diabetics and may prevent resulting complications.

UR - http://www.scopus.com/inward/record.url?scp=78650905604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650905604&partnerID=8YFLogxK

U2 - 10.1089/ars.2010.3134

DO - 10.1089/ars.2010.3134

M3 - Article

VL - 14

SP - 353

EP - 366

JO - Antioxidants and Redox Signaling

JF - Antioxidants and Redox Signaling

SN - 1523-0864

IS - 3

ER -